Publications 2001

  1. Challenges for Model-Based Economic Evaluations of Post-Menopausal Osteoporosis Interventions. Osteoporosis International 2001;12(10):849-857. Tosteson ANA, Jönsson B, Grima DT, O'Brien BJ, Black, DM, Adachi JD.
  2. Coding Accuracy of Drug Claims Data in the Ontario Drug Benefit Database. Can J Clin Pharmacol. (forthcoming). Levy, AR, O'Brien BJ, Sellors C, Grootendorst P, Willan D.
  3. Cost-Effectiveness of Beta-Blocker Therapy with Metoprolol or with Carvedilol for Treatment of Heart Failure in Canada American Heart Journal, 2001;142(3):537-543. Levy AR, Briggs AH, Demers C, O'Brien BJ.
  4. Cost -Effectiveness of a Multi-drug Pre-packaged Regimen (Hp-PAC) for H. pylori Eradication in Canada. PharmacoEconomics, 2001;19(8):831-843. Agro K, Blackhouse G, Goeree R, Willan AR, Huang J-O, Hunt R, O'Brien BJ.
  5. Cost-Effectiveness of the Implantable Cardioverter Defibrillator. Results from the Canadian Implantable Defibrillator Study (CIDS) Circulation 2001;103:1416-1421. O'Brien BJ, Connolly SJ, Goeree R, Blackhouse G, Willan A, Yee R, Roberts RS, Gent M (for the CIDS investigators).
  6. Cost-Effectiveness Analysis when the Willingness to Accept is Greater than the Willingness to Pay. Statistics in Medicine 2001; 20:3251-3259. Willan A, O'Brien B, Leyva R.
  7. Cost Prediction Models for the Comparison of Two Groups. Health Economics, 2001:5(1):20-26. Willan A, O'Brien BJ.
  8. Examining the Saskatchewan Health Drug Database for Antidepressant Use: The case of fluoxetine. Canadian Journal of Clinical Pharmacology, 2001;8(3):146-152. Joffe RT, Iskedjian M, Einarson TR, O'Brien BJ, Stang M.
  9. Economic Evaluation of a New Acellular Vaccine for Pertussis in Canada. Pharmacoeconomics, 2001;19(5, Pt 2):551-563. Iskedjian M, Einarson TR, O'Brien BJ, DeSerres JG, et al.
  10. Effectiveness, Efficiency, and NICE. A NICE start but evidence costs money (Editorial). British Medical Journal, 2001;322;943-944. Sculpher MJ, Drummond M, O'Brien B.
  11. Investigating Extrathoracic Metastatic Disease in Patients with Apparently Operable Lung Cancer. Ann Thorac Surg 2001;71:425-34. The Canadian Lung Oncology Group (Guyatt G, Casson A, Cook D, DesLauriers J, Griffith L, Inculet R, Johnston M, Lefcoe M, Miller J, O'Brien B., Todd T, Winton T.)
  12. The Death of Cost-Minimisation Analysis? Health Economics, 2001 Mar 10:2 179-84. Briggs AH, O'Brien BJ.
  13. The Effect of Clinical Risk Stratification on the Cost-Effectiveness of the iIplantable Cardioverter Defibrillator: The Canadian Implantable Defibrillator Study. Circulation 2001;104:1622-1626. Sheldon R, O'Brien BJ, Blackhouse G, Goeree R, Mitchell B, Klein G, Roberts RS, Gent M, Connolly SJ, for the CIDS investigators.
  14. The Impact of Reference Pricing of Nitrates on the Use and Costs of Anti-Anginal Drugs. Canadian Medical Association Journal, 2001;165(8):1011-1019. Grootendorst P, Dolovich L, O'Brien B, Holbrook A, Levy A.
Toronto Web Design by LinxSmart
Graphic Design by Electra